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ABSTRACT
Hydroxytyrosol (HT), a polyphenol of olive oil, downregulates epidermal growth 
factor (EGFR) expression and inhibits cell proliferation in colon cancer (CC) cells, 
with mechanisms similar to that activated by the EGFR inhibitor, cetuximab. Here, 
we studied whether HT treatment would enhance the cetuximab inhibitory effects on 
cell growth in CC cells.
HT-cetuximab combination showed greater efficacy in reducing cell growth in HT-
29 and WiDr cells at concentrations 10 times lower than when used as single agents. 
This reduction was clearly linked to cell cycle blockade, occurring at G2/M phase. The 
cell cycle arrest in response to combination treatment is related to cyclins B, D1, and 
E, and cyclin-dependent kinase (CDK) 2, CDK4, and CDK6 down-regulation, and to 
the concomitant over-expression of CDK inhibitors p21 and p27. HT and cetuximab 
stimulated a caspase-independent cell death cascade, promotedtranslocation of 
apoptosis-inducing factor (AIF) from mitochondria to nucleus and activated the 
autophagy process.
Notably, normal colon cells and keratinocytes were less susceptible to combo-
induced cell death and EGFR downregulation.
These results suggest a potential role of diet, containing olive oil, during 
cetuximab chemotherapy of colon tumor. HT may be a competent therapeutic agent 
in CC enhancing the effects of EGFR inhibitors.
INTRODUCTION
Hydroxytyrosol (HT), 2-(3,4-dihydroxyphenyl)
ethanol, a polyphenol found in olive oil, noted for its anti-
inflammatory, antioxidant activity, has been reported to 
reduce proliferation of human cancer cells, particularly 
colon carcinoma cells [1–3], and to exert pro-apoptotic 
effects [4–6]. Epidemiological studies substantiated the 
association between olive oil consumption and cancer 
prevention [7, 8], and a plethora of studies highlighted 
the beneficial properties of olive oil polyphenols due 
to their protective activity on DNA damage, lipid 
peroxidation and ROS generation [9–11]. Recently, we 
described the inhibition of HT on HT-29 colon cancer 
cell proliferation, which leads to a reduction of tumor-
mass growth in a mouse HT-29 xenograft model. We also 
uncovered a possible mechanism, as we found that HT 
markedly accelerates degradation of EGFR, by promoting 
phosphorylation of the docking site for Cbl, a component 
of the ubiquitin system [3].
These findings suggest the existence of causal 
relationship between the HT polyphenol and the EGFR 
burden, widely recognized as the main driver of colon 
cancer growth. To exploit this concept we designed a 
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study to investigate the influence of HT on the anticancer 
efficacy of cetuximab, a monoclonal antibody against 
EGFR known to produce EGFR downregulation, and 
the ensuing tumor growth inhibition and cell apoptosis. 
Accordingly, we compared the effects exerted by exposure 
to HT and cetuximab as single agents and by the HT-
cetuximab combination on HT-29 and WiDr colon cancer 
cells, examining functional parameters of tumor growth 
and clonogenic potential, as well as biochemical ones. 
Among the latter we analyzed: EGFR expression, cell 
Figure 1: Low concentrations of HT and cetuximab reduce cell growth in colorectal cancer. HT-29 (A), and WiDr (D) cells 
were exposed to increasing HT concentrations in presence/absence of EGF (5 ng/ml) for 48 h. Cell viability values, reported as absorbance 
at 540 nm, were obtained by MTT assay. Numbers represent mean ± DS of three experiments run in triplicate ** P <0.01, *** P <0.001 
vs. untreated cells. ## P <0.01, ### P <0.01 vs. EGF-treated cells. HT-29 (B), and WiDr (E) cells were exposed to increasing cetuximab 
concentrations in presence/absence of EGF (5 ng/ml). Values obtained as in A. Numbers represent mean ± DS of three experiments run in 
triplicate. ** P <0.01 vs. untreated cells ## P <0.01, ### P <0.001 vs. EGF-treated cells. HT-29 (C), and WiDr (F) cells were exposed to HT 
(10 μM) and/or cetuximab (1 μg/ml) in presence/absence of EGF (5 ng/ml) for 48 h. These concentrations were used throughout this work, 
unless otherwise noted. Values obtained as in A. *** P <0.001, vs. untreated cells. ### P <0.001 vs. EGF-treated cells. §§ P < 0.01. §§§ P 
<0.001, vs. HT or cetuximab (alone) treated cells.
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cycle progression molecules, apoptosis and autophagy 
markers and genes.
The HT-cetuximab combination, containing a 
fraction (ca. 1/10) of the maximal effective dose of each 
single agent, produced a far greater anti-tumor effect, in 
terms of inhibition of cell proliferation and clonogenic 
potential. Similarly, we observed consistent changes of 
biochemical parameters, such as EGFR expression, cell 
cycle check-point proteins and apoptosis, and autophagy 
markers.
Moreover, normal colon cells and human 
keratinocytes were less susceptible to cell death and 
EGFR downregulation induced by the combo-treatment. 
Interestingly, a number of recent reports have described 
the enhancement exerted by other polyphenols (e.g. 
curcumin, resveratrol) on chemotherapeutic agents on 
cancer progression [12, 13].
The striking enhanced efficacy on tumor cells 
and reduced effects on normal cells of the compound 
combination mentioned above might have implication in 
designing chemotherapeutic regimen for advanced colon 
cancer patients.
RESULTS
Growth of colon cancer cells exposed to HT and 
cetuximab
First, we determined the sensitivity of HT-29 and 
WiDr cells towards HT (1 up to 300 μM) or cetuximab 
(0.01, up to 100 μg/ml) alone or in presence of epidermal 
growth factor (EGF) for 48 h. Cells treated with 0.1% FBS 
were used as basal control.
The MTT assay revealed that HT reduced cell 
viability at the highest concentration (300 μM, P<0.001) 
in basal conditions, while it reduced cell proliferation in 
EGF-treated cells in a concentration dependent manner 
(Figure 1A–1D). HT IC
50
 values were 136.7 and 163.4 
μM in HT-29 and WiDr cell lines, respectively. Marked 
differences in sensitivity to cetuximab were observed 
in colon cancer cells primed with EGF, as HT-29 cell 
growth was reduced by high cetuximab concentrations 
(10-100 μg/ml; IC
50
 50.12 μM), while WiDr cells were 
unaffected by mAb at any concentration tested (compare 
Figure 1B with 1E). Cetuximab was ineffective on cell 
growth in control condition. High concentration of either 
HT (100-300 μM) or cetuximab (100 μg/ml) reduced the 
cell number compared to control condition, therefore 
useless for the scope of this work. In other experiments 
reported herein they were reduced to 10 μM and 1 μg/ml 
(HT and cetuximab, respectively) and served also for the 
HT-cetuximab combination (see below).
Then, we tested the combination of HT (10 μM) 
with cetuximab (1 μg/ml) for its effect on HT-29 and WiDr 
cell proliferation ability. As we noted a significant growth 
inhibition of the combination either in basal condition or 
in EGF-treated cells (Figure 1C and 1F), we conclude that 
HT enhances efficacy of cetuximab on tumor cells.
HT and cetuximab reduce HT-29 and WiDr 
colony formation
We next analyzed HT (10 μM) and cetuximab (1 μg/
ml) combination on cell growth by using the functional 
clonogenic assay, that more closely replicates the growth 
characteristics of tumors in vivo. As shown in Figure 
2A and 2B, EGF induced colony formation in both HT-
29 and WiDr cells. Combination of HT and cetuximab 
significantly reduced colony formation both in basal and 
in EGF-treated cells. In both cancer cell lines, a slight 
reduction of clonogenic potential was observed also in 
presence of cetuximab alone (Figure 2A and 2B), while 
HT per se promoted a slight reduction of WiDr cells 
colonies only (Figure 2A).
HT enhances cetuximab-mediated EGFR 
expression decline
Since reports from our and other laboratories 
showed that HT reduces EGFR expression [3] and 
cetuximab down-regulates EGFR levels in colon cancer 
cells [14], we investigated whether HT and cetuximab per 
se and in combination, when used at low concentrations, 
would affect EGFR expression in HT-29 and WiDr cells 
(Figure 3). Low concentration of HT and cetuximab did 
not reduce EGFR expression when administered per se, 
while induced a marked decline of EGFR levels when co-
administered together, as assessed either by western blot 
or immunofluorescence (Figure 3A–3D). As expected, 8 
h of treatment with high concentration of HT (100 μM) 
or cetuximab (10 μg/ml) reduced EGFR levels in both 
cell lines (Figure 3C and 3D; compare panels e and f vs 
panel a, and also Figure 3E and 3F) [3]. All together the 
data suggests that the combination of HT with cetuximab 
inhibits cell growth by targeting EGFR levels in colon 
cancer cells.
HT and cetuximab combination arrests colon cell 
cycle at G2 phase
In light of the cooperation observed between HT and 
cetuximab, we examined whether the growth inhibition 
might be attributed to cell cycle arrest. HT-29 and WiDr 
cells were treated (48 h) with EGF in the presence/
absence of HT (10 μM) and cetuximab (1 μg/ml) per se 
or in combination, and labelled with propidium iodide 
(PI) to detect cell cycle progression by flow cytometry 
(Figure 4). Results showed that the treatment with HT 
or cetuximab did not affect the cells residing in the 
different phases of the cell cycle, while the combination 
of the two compounds caused a significant increase in 
the apoptotic cells represented by sub G
0
/G
1
 population 
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(Figure 4A and 4B, and Supplementary Tables 1 and 2). 
Interestingly, in EGF-treated colon cancer cells, the HT-
cetuximab combination challenge caused a significant 
increase in the sub G
0
/G
1
 population (Figure 4A and 4B, 
grey bars and Supplementary Tables 1 and 2), which was 
accompanied by accumulation of cells at G2/M- and by 
a decrease in those in S-phase (Figure 4A and 4B, black 
and dark grey bars, respectively, and Supplementary 
Tables 1 and 2). Detailed analysis revealed, in fact, 
that the co-treatment with HT and cetuximab induced 
a 3-fold and a 2-fold increase in the cells in sub G
0
/G
1
- 
and G2/M-phase, respectively, while it halved those in S 
phase (Supplementary Tables 1 and 2), suggesting DNA 
fragmentation and apoptosis process in colon cancer cells.
HT-cetuximab combination adversely affects cell 
cycle checkpoint proteins in colorectal cancer 
cells
Analysis of the cell regulator proteins, CDKs and 
CDKi expression, revealed that the HT-cetuximab combo 
induced a significant increase in CDKi p27 and p21 
expression, known to be involved in either G
1
, or G2, or 
S phase arrest, while p18 expression (barely detectable 
Figure 2: Combination of low concentrations of HT and cetuximab reduces colony formation of colorectal cancer cells. 
Colony formation capability of HT-29 (A), and WiDr (B) cells in response to HT (10 μM) and/or cetuximab (1μg/ml) in presence/absence 
of EGF (5 ng/ml). Colonies (>75 cells) with 50% efficiency were counted. Results are expressed as surviving factor (SF, see material and 
methods). ** P <0.01, *** P <0.001, vs. untreated cells. # P <0.05, ### P <0.001 vs. EGF-treated cells.§ P < 0.05. §§ P <0.01, vs. HT or 
cetuximab (alone) treated cells.
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Figure 3: EGFR expression in colorectal cancer cells treated with HT and cetuximab alone or combined. HT-29 (A) and 
WiDr (B) cells were exposed to low concentration of HT or cetuximab alone or in combination for 8 h and EGFR proteins was analyzed 
by western blot. Images of immunostaining in HT-29 (C) and WiDr (D) for EGFR (green) and DAPI (blue) in tumor cells exposed to 10 
% FBS (a), cetuximab 1 μg/ml (b), HT 10 μM (c), cetuximab 1 μg/ml + HT 10 μM (d), cetuximab 10 μg/ml (e), HT 100 μM (f). Confocal 
images were captured with Leica SP5 confocal using 63x objective, scale bars 20 μm. HT-29 (E) and WiDr (F) cells were exposed to high 
concentration of HT or cetuximab for 8 h and EGFR proteins were analyzed by western blot. β-actin has been used to normalized loading 
(in Figures 3 and 7). Quantification (termed analysis in Figures 3 and 7; arbitrary density unit, A.D.U.) has been reported. ** P <0.01; *** 
P <0.001 vs. untreated cells; ### P <0.001 vs single agents.
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in the WiDr line) was mostly unchanged in colon cancer 
cells (Figure 5A and 5D Supplementary Tables 3 and 
4). Furthermore, the combination reduced cyclin D1, 
D3, E1, CDK2, CDK4 and CDK6 expression, cell cycle 
regulators that mediate the transition from G
1
 to S phase, 
and it decreased cyclin B1, a key regulator of cells entry 
into mitosis (transition from G2 to M phase) (Figure 5B, 
5C, 5E and 5F and Supplementary Tables 5–8). Thus, the 
HT-cetuximab combination induces G
1
/S and G2/M phase 
cell cycle arrest by reducing the expression of cell cycle 
regulators. (Figure 5 and Supplementary Tables 3 and 
4) Of note, the concomitant downregulation of D3 and 
CDK6, recently reported, might disrupt the cancer-specific 
metabolic pathways (pentose and serine), and therefore 
deprive the cells of pivotal molecules such as NADPH 
and glutathione [15].
Figure 4: Cell cycle analysis in cancer cells treated with low concentration of HT and cetuximab combined. HT-29 (A), 
and WiDr (B) cells were exposed to HT or cetuximab alone or in combination in presence or absence of EGF for 48 h. The percentage 
of cells at each stage of the cell cycle was analyzed by flow cytometry after DNA staining with propidium iodide. Quantification of cells 
residing in G
0
 and G
1
 for HT-29 (C), and WiDr (D) are reported. Percent of HT-29- (C), and WiDr-cells (D) in sub Go/G
1
 phase. *** P 
<0.001, vs. untreated cells. §§§ P <0.001, vs. HT or cetuximab (alone) treated cells.
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HT-cetuximab combination induces cell death by 
activating apoptosis and autophagy processes
The observed cell cycle arrest exerted by the 
combination provided a strong clue for studying the fate 
of colon cancer cells following exposure to the examined 
drugs. Accordingly, we investigated a number of apoptosis 
and autophagy markers with aim of determining the 
relevance of each process in the fate of cancer cells after 
the above treatment. Indeed, we found a robust increase of 
the apoptotic marker phosphatidylserine (immunostaining) 
solely in colon cancer cells exposed to HT-cetuximab 
Figure 5: HT and cetuximab combination modulate the cell cycle checkpoint proteins in colorectal cancer cells. HT-29 
(A, B, C), and WiDr (D, E, F) cells were exposed to HT or cetuximab, alone or in combination in presence of EGF for 48 h and the cell 
cycle checkpoint proteins were analyzed by western blot.
Oncotarget83214www.impactjournals.com/oncotarget
combination, compared to control or to single agents 
per se (Figure 6A–6D). In contrast the levels of cleaved 
caspase-3 (Figure 6E and 6F) were unaffected. This 
clearly indicates that colon cancer cell death occurs in a 
caspase-3-independent way.
Further insight was obtained by evaluating the 
cellular localization of AIF, an inducer of the caspase-
independent pathway, which translocates to the nucleus in 
response to death stimuli. We found that the HT-cetuximab 
combination, but not the single agents per se, provoked 
AIF cytosolic and nuclear accumulation, while depriving 
Figure 6: HT and cetuximab combination induces caspace3-independent apoptosis in colorectal cancer cells. 
Phosphatidylserine (red) and DAPI (blu) exposure, assessed by immunofluorescence, in HT-29 (A, C for quantification) and WiDr (B, D 
for quantification) cells treated for 48 h with 10% FBS (Ctr) (a), cetuximab 1 μg/ml (b), HT HT 10 μM (c) or cetuximab 1 μg/ml+ HT 10 
μM. Confocal images were captured with Leica SP5 confocal using 40 x objective, scale bars 60 μm.*P<0.05; **P <0.01 vs. untreated 
cells; §P<0.05; §§P<0.01 vs. HT- or cetuximab-treated cells. HT-29 (E), and WiDr (F) cells were exposed to HT or cetuximab alone or in 
combination for 8 h and caspase-3 activity were analyzed by western blot. A.D.U.(cleaved caspase-3 vs. total caspase-3) has been reported.
Oncotarget83215www.impactjournals.com/oncotarget
mitochondria (Figure 7A and 7B). Immunofluorescence 
showed AIF an even granular distribution in cellular 
compartments, likely mitochondria, in control and single 
agent-treated cancer cells, contrasting with the striking 
nuclear accumulation in the combination–treated cells 
(Figure 8A and 8B). This suggest that the HT-cetuximab 
combination induces apoptosis in cancer cells via 
mitochondrial dysfunction, AIF translocation in nucleus 
and DNA fragmentation.
Assessment of autophagy markers such as the 
microtubule-associated protein light chain 3 in its 
processed form, LC-3II, and the autophagy related gene 7, 
Atg7, as well as Beclin-1 levels, which were consistently 
overexpressed in colorectal cancer cells treated with HT-
cetuximab combination relative to control and single 
agent treatment (Figure 9A and B), provided evidence that 
autophagy contributes to the anti-proliferative activities 
and apoptotic events described above.
HT-cetuximab combination preserves normal 
colon cells and skin keratinocyte functions
We investigated whether the HT-cetuximab 
combination affected the normal colon cells and human 
keratinocytes, in terms of proliferative ability, reproducing 
the effects observed in colon cancer cells over single 
agents treatment. To this end, we used CCD-18Co (normal 
fibroblast colon cells), or differentiated CaCo2 cells 
(mimicking intestinal cells) and human keratinocytes 
(HaCaT) evaluating cell survival and other parameters. 
Figure 7: HT and cetuximab combination stimulates AIF release from the mitochondria to the cytoplasm and nuclear 
translocation. (A) HT-29 (upper panel) and (B) WiDr (bottom panel) cells were exposed to HT or cetuximab alone or in combination for 
24 h. Cytoplasmic, nuclear, and mitochondrial fractions were analyzed for AIF, tubulin (cytosolic marker), COX IV (mitochondrial marker) 
and lamin (nuclear marker) expression and localization Cytoplasmic AIF fraction was normalized with tubulin, nuclear fraction with lamin 
and mitochondrial fraction with COX IV. ***P<0.001 vs.
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The HT-cetuximab combination affected neither the cell 
survival ability (Figure 10A–10C) nor EGFR expression 
levels in CCD-18Co cells or in differentiated CaCo2 cells 
(Figure 10D), indicating that its effect is specific for tumor 
cells. Further, on HaCaT cells expression of claudin-1 
and Occludin proteins at the cell-to-cell contacts was 
only marginally affected, while at higher concentration 
cetuximab promoted a significant subversion of both 
proteins distribution on cell membranes (Figure 11A and 
11B, panel e vs panel a). Altogether, these results indicate 
that HT-cetuximab combination exerts an antitumor 
effect on colorectal cancer without affecting normal 
colon cell function and the skin barrier of keratinocytes, 
possibly curtailing the dermatologic toxicity and diarrhea 
frequently associated with the conventional cetuximab 
dose regimen in cancer patients.
Figure 8: HT and cetuximab combination stimulates AIF release from the mitochondria to the cytoplasm and nuclear 
translocation evaluated by immunofluorescence. Images of immunostaining for AIF (green) and DAPI (blue) in HT-29 (A) and 
WiDr (B) cells treated with 10 % FBS (a), cetuximab 1 μg/ml (b), HT 10 μM (c) or cetuximab 1 μg/ml+ HT 10 μM (d). Arrows indicate 
nuclei with AIF translocation. Boxed areas are shown in detail above the pictures. Confocal images were captured with Leica SP5 confocal 
using 63x objective, scale bars 20 μm.
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DISCUSSION
Epithelial growth factor (EGF), via its receptor 
EGFR, elicits proliferation in many human cancers [16]. 
Here, we describe the effect of two molecules, cetuximab 
and HT, a polyphenol from olive oil, that impair the EGF/
EGFR oncogenic drive, yielding a reduced proliferation 
of colon cancer cells (see Figure 10). Whereas cetuximab, 
a monoclonal antibody, occludes the EGFR binding 
sites, HT accelerates the EGFR degradation through 
ubiquitination. Although the two molecules affect tumor 
proliferation by disparate mechanism, it is possible that 
these agents might cooperate in producing an enhanced 
anti-tumor effect as they address the same molecular 
target. Evidence for cooperativity was found in functional 
experiments when HT and cetuximab combination (10 
μM and 1 μg/ml respectively), produced greater EGFR 
signaling impairment than that elicited by the single 
agents in the colon cancer cells examined (HT-29 and 
WiDr). This was observed in experiments measuring either 
the cancer cell proliferative ability or their clonogenic 
propensity in response to EGF (see Figures 1 and 2). 
An even greater effect was detected by measuring the 
expression levels of EGFR, as we found a sharp decline 
of oncogene expression in colonic cancer cells exposed to 
the above combination, compared to the negligible or null 
effects exerted by the single agents (see Figure 3).
Analysis of cell cycle progression in cancer cells 
provided a rationale for the observed functional effects of 
Figure 9: HT and cetuximab combination induces autophagy in colorectal carcinoma cells. HT-29 (A) and WiDr (B) cells 
were exposed to HT or cetuximab alone or in combination for 24 h and the LC3, Atg7 and Beclin-1 proteins were analyzed by western blot. 
Quantification (C for HT-29 cells and D for WiDr cells) has been reported. *** P< 0.001 vs. HT-cetuximab combination.
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Figure 10: HT-cetuximab combination reduces side effects of cetuximab treatment in colorectal cancer. CCD-18Co 
(A), differentiated CaCo2 (B) and HaCaT (C) cells were exposed to the indicated concentration of HT and cetuximab in presence/absence 
of EGF (5 ng/ml) for 48 h. Cell survival values, reported as absorbance at 540 nm, were obtained by MTT assay. *P<0.05; **P<0.01 
vs. untreated cells; §P<0.05; §§P<0.01 vs. cetuximab 10 μg/ml alone; çP<0.05, ççP<0.01 vs EGF-treated cells; #P<0.05, ##P<0.01 vs 
cetuximab 10 μg/ml plus EGF-treated cells. CCD-18Co (D, upper panel) and differentiated CaCo2 (D, bottom panel) cells were exposed 
to HT or cetuximab alone or in combination for 8 h and EGFR proteins was analyzed by western blot. CCD-18Co (E) and differentiated 
CaCo2 (F) cells were exposed to cetuximab (10 μg/ml) alone for 8 h and EGFR proteins were analyzed by western blot. β-actin has been 
used to normalize loading. A.D.U. has been reported. ***P<0.001 vs. untreated cells.
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Figure 11: HT-cetuximab combination reduces side effects of cetuximab treatment in colorectal cancer in HaCaT cells. 
Images of immunostaining for occludin (green) (G), claudin1 (H) and DAPI (blue) in HaCaT cells treated with 10 % FBS (a), cetuximab 
1 μg/ml (b), HT 10 μM (c), cetuximab 1μg/ml + HT 10 μM (d), cetuximab 10 μg/ml (e). Confocal images were captured with Leica SP5 
confocal using 63x objective, scale bars 20 μm.
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the compounds examined, indicating also the underlying 
mechanism of action.
In fact, the HT-cetuximab combination was found 
to induce growth arrest at G2/M phase, contrasting with 
the negligible or null effect exerted by the single agents 
in this phase and in the following ones. The increase in 
cell number at G2/M phase was associated with the CDK 
inhibitors p21 and p27 induction [17–20], the former being 
known to silence the G
1
/S-promoting cyclin E/CDK2 
kinase and thereby to cause a G
1
 arrest [19]. Accordingly, 
cyclin E and CDK2 kinases were found to be decreased 
by the combination. The G
1
/S checkpoint, governed by 
two mechanisms converging into p21, are commonly 
deregulated in human colon cancer [20, 21]. Moreover, 
the reduced cyclin B expression found in HT-cetuximab 
combination treated cells, signals an efficient blockade of 
the G2/M checkpoint which prevents cells from initiating 
mitosis in presence of DNA lesions or not fully replicated 
DNA [17, 18, 20, 22]. Further complexity of the cell 
cycle arrest arises from the recent observation showing 
Figure 12: Effects of HT-Cetuximab combination on tumor and normal epithelial cells. Cetuximab at 10 μg/ml, but not at 
1μg/ml, blocks the cell cycle in G
1
 phase, promotes apoptosis, and autophagy in colon tumor cells, and significantly reduces cell membrane 
junctions in normal epithelial cells (left vs. middle panel). The combination of Cetuximab 1μg/ml with low concentration of HT (10 μM) 
shows cytotoxic effects on tumor cells (inhibition of cell cycle in G2/M phase, induction of apoptosis and autophagy), without affecting 
normal epithelial cells (right panel vs. middle and left panels).
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that the down-regulation of Cyclin D3 and CDK6, as 
found in this work (see Figure 5 panel C trough F), has 
a strong impact on cancer-specific metabolic pathway 
(glycolysis), leading to mitochondrial dysfunction [15, 
23]. In agreement, in this work we obtained evidence for 
mitochondrial failure following combination treatment, as 
we observed AIF depletion in mitochondria (see Figure 
7). Although, previous studies reported that cetuximab 
blocks the cell cycle in G
1
 phase [24], this occurred 
at high concentrations (100 mg/ml). Conversely, the 
impairment of the EGF/EGFR system afforded by the 
HT and cetuximab combination appears to be related 
to its ability to mainly provoke a growth arrest in G2/M 
phases in colon cancer cells. Clearly, as a consequence 
of the ensuing DNA fragmentation observed in sub G
0
/
G
1
 phase of cell cycle, we detected an activation of the 
apoptotic and autophagy processes in colon cancer cells 
exposed to the HT and cetuximab combination. Although, 
we found an increased phosphatidylserine externalization, 
the unaffected caspase-3 expression in colon cancer cells 
exposed to HT and cetuximab combination indicated 
a caspase-independent apoptosis mechanism. AIF 
translocation from mitochondria into nuclei, a marker of 
caspase-independent apoptosis, suggested that apoptosis 
in cancer cells is possibly related to mitochondrial 
dysfunction. Autophagy activation, mainly detected by 
a sharp rise of Beclin-1 levels, is, to a greater extent, 
associated with the ubiquitin system stimulation promoted 
by HT. However, we cannot exclude that it was associated 
with other effects previously reported for cetuximab [25]. 
The contribution of autophagy in the anti-tumoral activity 
of the combination needs further investigations.
Of relevance, for its clinical implications, are the 
findings that the HT and cetuximab combination preserved 
the normal colon and skin epithelial functions [26] as 
it failed to affect the proliferation of CCD-18Co and 
CaCo2 cells, as well as the membrane junctions of human 
keratinocytes (see Figure 12).
In sum, the polyphenol HT combined with the anti-
EGFR antibody cetuximab, produces a robust inhibition 
of colon cancer cell growth, a remarkable effect that 
occurs at concentrations of each agent representing a 
fraction (approx. 1/10) of that producing near maximal 
effect as single molecules. Further, while the maximal 
effects of HT, as single compound, occur at concentrations 
borderline between physiological and pharmacological 
setting (100 μM), in the combination with the cetuximab, 
HT effects occur at physiological/nutritional setting (10 
μM), suggesting that a controlled diet containing olive oil, 
during chemotherapy of colon tumor might enhance the 
effects of EGFR inhibitors.
We show evidence that the two agents cooperate in 
reducing the oncogenic input to colon cancer cells by two 
linked mechanisms. First, they accelerate EGFR turnover 
through ubiquitination, and curtail EGFR receptor density, 
enabling a reduced concentration of cetuximab to exert 
tumor inhibitory efficacy. Second, they provoke a cell 
cycle arrest at G2/M phase by inducing the CDK inhibitors 
p21 and p27 expression and the ensuing the apoptotic 
process. Thus, these findings may provide a rational 
mechanistic framework for the health benefits reported 
in epidemiological studies on a variety of nutritional 
style, particularly the well-known mediterranean diet [12, 
13, 27]. Given the observed HT-induced down-shift of 
cetuximab potency, without compromising its antitumor 
efficacy, one wonders whether these findings might be 
translated into the cancer chemotherapy regimens in 
humans. This study suggests that an appropriate diet 
might considerably attenuate the severe side effects (e.g. 
skin and hematological disturbances) often associated 
with cetuximab and other agents with similar mechanism, 
which are commonly administered at maximal effective 
doses.
MATERIALS AND METHODS
Cell lines
HT-29 (passages 10-20, ATCC® HTB-38™) and 
WiDr (passages 5-20, ATCC® CCL-218™) human 
colorectal adenocarcinoma cells, CCD-18Co (passages 
2–15, ATCC® CRL-1459™) human colon fibroblast cells 
and CaCo2 (passages 12–20, ATCCR® HTB-37™) human 
colorectal adenocarcinoma cells differentiated in intestinal 
cells as described in the next section, were obtained 
from the American Type Culture Collection (ATCC, 
LGC Standards S.r.l, Italy). HaCaT cells (passages 3-7) 
immortalized human keratinocytes were acquired from 
Voden medical (Meda, MB, Italy). All the cell lines were 
certified by STRA and cultured as recommended.
All the cell lines were immediately expanded after 
delivery (up to 6 x 107 cells) and frozen down (1 x 106/
vial) such that all the cell lines could be restarted after a 
maximum of 10 passages every 3 months from a frozen 
vial of the same batch of cells. Control of mycoplasma 
was done from a frozen vial.
Differentiation of CaCo2 cell line
CaCo2 cells were seeded in T75 flasks at a density 
of 6.6 × 104 cells/ml and were maintained for 21 days of 
culture. Fresh complete growth medium was added every 
two days.
After the selection of 21-day cultured cells in T75 
flasks CaCo2 cells were differentiated cells and used as 
intestinal cells [28].
Reagents
Reagents were as follows: celLytic MT cell lysis 
reagent (C3228), anti-β-actin (A5441), DAPI (D9542), 
Fluoromount Aqueous Mounting Medium (F4680), Triton 
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X-100 (T8787), Vybrant MTT (M5655) and crystal violet 
(C3886, Sigma Aldrich, Milan, Italy); HT (70604, Cayman 
Chemicals, VinciBiochem, Vinci, Italy); EGF (100-008, 
RELIAtech, VinciBiochem, Vinci, Italy), cetuximab was 
kindly provided by Azienda Ospedaliera Universitaria 
Senese, Siena, Italy.
MTT assay
Cell proliferation was quantified by Vybrant MTT 
cell proliferation assay as described [29]. Briefly, cells (3 
x 103) were seeded in 96-multiwell plates in medium with 
10 % serum for 24 h and then exposed to HT (1, 3, 10, 30, 
100 or 300 μM, corresponding to the range 0.1542 – 46.26 
μg/ml), cetuximab (0.01, 0.1, 1, 10 or 100 μg/ml) with/
without EGF (5 ng/ml) for 48 h (with treatment of HT 
every 24 h). Data are reported as cell survival at 540 nm 
absorbance/well.
Cell fractionation assay
To obtain cytosolic, mitochondrial and nuclear 
fractions, 2.5 x106 cells were plated in two 10 cm diameter 
dishes, maintained in growth medium with 10 % FBS for 
18 h and then stimulated with HT (10 μM), cetuximab (1 
μg/ml) for 24 h. Cells were harvested by centrifugation at 
300 x g for 5 min and re-suspended in 5 ml of 1X Buffer 
A to 6.6 x 106 cells/ml from Abcam Cell Fractionation 
Kit (ab109719). Cell suspension was diluted with equal 
volume of Buffer B, incubated with constant mixing for 7 
min at RT, and centrifuged at 5,000 x g for 1 min at 4°C. 
The supernatant was centrifuged at 10,000 x g for 1 min 
at 4°C (cytosolic fraction). The pellet was re-suspended 
in Buffer A, and the suspension was diluted with equal 
volume of Buffer C, incubated with constant mixing for 10 
min at RT and centrifuged at 5,000 x g for 1 min at 4°C. 
The supernatant was centrifuged at 10,000 x g for 1 min at 
4°C (mitochondrial fraction). The pellet was re-suspended 
in Buffer A (this is the nuclear fraction). All fractions were 
analyzed for AIF (1:1,000, Cell Signaling). Western blot 
was performed as described [2]. Images were digitized 
with the program CHEMI DOC Quantity One, blots were 
analyzed in triplicate by densitometry using NIH Image 
1.60B5 software, and the results in arbitrary densitometric 
units (A.D.U.) were normalized for β-tubulin, COX IV or 
lamin (Sigma Aldrich).
Immunoblot analysis
Total protein lysates were obtained using celLytic 
MT cell lysis reagent as described [2]. Antibodies used 
are as follows: anti-EGFR (4267), anti-p18 (2986), 
anti-p21 (2947), anti-p27 (3686), anti-cyclin D1 (2926), 
anti-cyclin D3 (2936), anti-CDK2 (2546), anti-CDK4 
(2906), anti-CDK6 (3136), anti-cyclin B1 (4138), anti-
cyclin E1 (4129), anti-AIF (5318), anti COX IV (4850), 
anti-LC3 I and II (12741), anti-Atg-7 (8558), anti-beclin 
(3495) and anti-caspase 3 (9662, Cell Signaling, Leiden, 
the Netherlands). Cells were stimulated with HT (10 μM), 
cetuximab (1 μg/ml) with/without EGF (5 ng/ml) for 8, 24 
or 48 h (with administration of HT every 24 h). Images 
were digitalized with CHEMI DOC Quantity One program 
(Biorad, Hercules, CA, USA), blots were analyzed in 
triplicate by densitometry using NIH Image 1.60B5 
software, and the arbitrary densitometric units (A.D.U.) 
were normalized for β-actin.
Immunofluorescence
3x104 cells were cultured on coverslips, treated with 
HT (10-100 μM), cetuximab (1-10 μg/ml) with/without 
EGF (5 ng/ml) for 8-24 or 48 h (with treatment of HT 
every 24 h) and then fixed in paraformaldehyde (4%, 10 
min), washed in PBS and permeabilized, if necessary, 
with Triton X-100 (0.5% in PBS containing 0.5% BSA) 
and then incubated with BSA (45 min). Cells were then 
incubated for 16 h with anti-EGFR (1:40), anti-AIF (1:50, 
Cell Signaling), anti-phosphatedylserine (1:50, 05-719 
Merk Millipore), anti-occludin (1:80, 71-1500 ZYMED) 
diluted in PBS containing 0.5% BSA. To investigate 
phosphatedylserine externalization on cell membranes, 
cells were fixed in paraformaldehyde (4%, 10 min), 
washed in PBS, incubated with BSA (45 min) without 
permeabilization, and then incubate for 16 h with anti-
phosphatedylserine (1:50, 05-719 Merk Millipore) diluted 
in PBS containing 0.5% BSA. After incubation with the 
secondary antibody ALEXAFLUOR 488 anti-mouse 
or anti-rabbit (A11001, A11011 respectively; 1:200 1 h, 
Thermo Fisher), cells were washed and incubated with 
DAPI (1 μg/mL, 20 min), washed and the coverslips were 
mounted in Fluoromount Aqueous Mounting Medium.
Cell cycle
Cell cycle distribution was analyzed using flow 
cytometry after propidium iodide staining. Colon cells 
(7 x 105) were seeded in 6-multiwell plates in growth 
medium with 10% serum for 24 h, left overnight to allow 
for cell attachment, and then exposed to 0.1 % serum for 
24 h and then treated with HT (10 μM), cetuximab (1 μg/
ml) with/without EGF (5 ng/ml) for 48 h (with treatment 
of HT every 24 h). Cells were then washed three times 
with PBS, trypsinized and collected by centrifugation 
at 0.3 x g for 5 min. The cells were fixed overnight in 
80% ethanol at −20°C, then washed twice with PBS and 
incubated with 0.5 ml of PBS containing 100 μg/ml RNase 
(R6148, Sigma Aldrich) and 50 μg/ml propidium iodide 
(P4170, Sigma Aldrich) at 37° C for 30 min. Cell cycle 
distribution was analyzed by measuring DNA content 
using a flow cytometer (BD Bioscences, Milan, Italy). 
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Data are analyzed in triplicate by Cell Quest Pro, BD [30, 
31].
Clonogenic assay
For clonogenic assay, HT-29 and WiDr cells, were 
stimulated with HT (10 μM) and cetuximab (1 μg/ml) for 
48 h (with treatment of HT every 24 h) with/without EGF 
(5 ng/ml). Following treatments, cells were plated in 60 
mm culture dishes (at a density of 1,000 cells/dish) in 
medium containing 1% fetal calf serum, and then kept in 
a humidified incubator at 37° C and 5% CO2 for 2 weeks. 
Colonies (400 cells) with 50% plate efficiency were fixed 
and stained with 0.05% crystal violet in 10% ethanol and 
counted. Data are expressed as surviving factor (SF), that 
indicates the number of colonies that arise after treatment 
of cells, expressed in terms of PE (PE is the ratio of the 
number of colonies to the number of cells seeded) [32].
SF no  of colonies formed after treatment
no  of cells seed
=
.
. ed X PE
Statistical analysis
Results are expressed as means ± SD or ±SEM. 
Statistical analysis was carried out using Student's t test, 
two-away ANOVA, followed by Bonferroni post-test for 
multiple comparison. P<0.05 was considered statistically 
significant.
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